#BIO22: Are biotech buy­outs fi­nal­ly com­ing in­to vogue? Here's what to look for in H2 M&A

If you want an idea of the kind of biotech M&A deals to ex­pect in H2, look at the re­cent spate of buy­outs.

End­points News talked with a phar­ma in­vest­ment banker, an ex­pe­ri­enced deal­mak­er, a fi­nance pro­fes­sor at MIT and a top an­a­lyst to find out what’s cen­ter stage these days in the M&A scene, as the bear mar­ket mauls biotech stocks and eras­es fol­low-on op­por­tu­ni­ties.

The trend of ac­quir­ing late-stage biotech com­pa­nies is ex­pect­ed to con­tin­ue in­to the sec­ond half of the year, sources told End­points. But while there are signs of hope for a quick­ened pace of M&A — Bris­tol My­ers Squibb’s an­nounce­ment it would ac­quire clin­i­cal-stage pre­ci­sion on­col­o­gy com­pa­ny Turn­ing Point Ther­a­peu­tics for a 122% pre­mi­um over the pre­vi­ous clos­ing price made some ques­tion if the bear mar­ket may fi­nal­ly be over — there aren’t any guar­an­tees.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.